MARKET

VBLT

VBLT

VASCULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.480
+0.051
+3.58%
Closed 16:00 01/24 EST
OPEN
1.450
PREV CLOSE
1.429
HIGH
1.480
LOW
1.425
VOLUME
198.45K
TURNOVER
--
52 WEEK HIGH
1.900
52 WEEK LOW
0.9300
MARKET CAP
53.10M
P/E (TTM)
-2.9594
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VBLT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VBLT News

  • We're Hopeful That Vascular Biogenics (NASDAQ:VBLT) Will Use Its Cash Wisely
  • Simply Wall St..6d ago
  • VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study
  • GlobeNewswire.01/08 13:00
  • UPDATE 2-Mexico's Televisa wins injunction on part of Disney-Fox deal; merger unaffected
  • Reuters.12/06/2019 03:03
  • UPDATE 1-Televisa wins injunction over Disney purchase of Fox assets in Mexico
  • Reuters.12/05/2019 20:32

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About VBLT

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.
More

Webull offers Vascular Biogenics Ltd (VBLT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.